Manuela Tutolo1, Enrico Ammirati2, John Heesakkers3, Thomas M Kessler4, Kenneth M Peters5, Tina Rashid6, Karl-Dietrich Sievert7, Michele Spinelli8, Giacomo Novara9, Frank Van der Aa10, Dirk De Ridder10. 1. Department of Urology, University Hospitals Leuven, Leuven, Belgium; Department of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy. Electronic address: tutolo.manuela83@gmail.com. 2. Department of Urology, Ospedale San Giovanni Battista, Turin, Italy. 3. Department of Urology 610, Radboud University Medical Center, Nijmegen, The Netherlands. 4. Department of Neuro-Urology, Balgrist University Hospital, Zurich, Switzerland. 5. Department of Urology, Beaumont Hospital, Royal Oak, MI, USA. 6. Functional Urology and Gender Services, Imperial College Healthcare NHS Trust, Charing Cross Hospital, London, UK. 7. University of Rostock Urology Clinic, Rostock, Germany; Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria. 8. Spinal Unit, Division of Neurourology, A. Zanollo Center for Sacral Area Disfunction, Ospedale Niguarda, Milan, Italy. 9. Department of Surgery, Oncology, and Gastroenterology - Urology Clinic, University of Padua, Padua, Italy. 10. Department of Urology, University Hospitals Leuven, Leuven, Belgium.
Abstract
CONTEXT: Neuromodulation is considered in patients with non-neurogenic lower urinary tract dysfunction (LUTD) not responsive to conservative treatment. OBJECTIVE: To systematically review the available studies on efficacy and safety of sacral neuromodulation (SNM) and percutaneous tibial nerve stimulation (PTNS) in non-neurogenic LUTDs not responsive to conservative treatments. EVIDENCE ACQUISITION: A literature research was conducted in PubMed/Medline and Scopus, restricted to articles in English, published between January 1998 and June 2017, with at least 20 patients and 6 mo of follow-up. EVIDENCE SYNTHESIS: Twenty-one reports were identified. Concerning SNM, the improvement of ≥50% in leakage episodes ranged widely between 29% and 76%. Overall dry rate ranged between 43% and 56%. Overall success/improvement rate in PTNS varied between 54% and 59%. Symptom improvement or efficacy in interstitial cystitis/bladder pain syndrome patients appeared to be lower compared with other indications in both techniques. Safety data showed fewer side effects in patients submitted to PTNS. CONCLUSIONS: Neuromodulation gives good results and is a safe therapy for patients with overactive bladder or chronic nonobstructive urinary retention with long-lasting efficacy. Moreover, PTNS has been shown to have good success rates and fewer side effects compared with SNM. These data have to be confirmed with long-term follow-up. PATIENT SUMMARY: Sacral neuromodulation can improve low urinary tract symptoms in selected patients; it appears to be a safe therapy for nonresponders to standard medical therapies. Percutaneous tibial nerve stimulation (PTNS) is a less invasive technique that gives good results in short time with fewer side effects. However, we must consider that PTNS has not been tested in the long term and results are lower if compared with SNM.
CONTEXT: Neuromodulation is considered in patients with non-neurogenic lower urinary tract dysfunction (LUTD) not responsive to conservative treatment. OBJECTIVE: To systematically review the available studies on efficacy and safety of sacral neuromodulation (SNM) and percutaneous tibial nerve stimulation (PTNS) in non-neurogenic LUTDs not responsive to conservative treatments. EVIDENCE ACQUISITION: A literature research was conducted in PubMed/Medline and Scopus, restricted to articles in English, published between January 1998 and June 2017, with at least 20 patients and 6 mo of follow-up. EVIDENCE SYNTHESIS: Twenty-one reports were identified. Concerning SNM, the improvement of ≥50% in leakage episodes ranged widely between 29% and 76%. Overall dry rate ranged between 43% and 56%. Overall success/improvement rate in PTNS varied between 54% and 59%. Symptom improvement or efficacy in interstitial cystitis/bladder pain syndrome patients appeared to be lower compared with other indications in both techniques. Safety data showed fewer side effects in patients submitted to PTNS. CONCLUSIONS: Neuromodulation gives good results and is a safe therapy for patients with overactive bladder or chronic nonobstructive urinary retention with long-lasting efficacy. Moreover, PTNS has been shown to have good success rates and fewer side effects compared with SNM. These data have to be confirmed with long-term follow-up. PATIENT SUMMARY: Sacral neuromodulation can improve low urinary tract symptoms in selected patients; it appears to be a safe therapy for nonresponders to standard medical therapies. Percutaneous tibial nerve stimulation (PTNS) is a less invasive technique that gives good results in short time with fewer side effects. However, we must consider that PTNS has not been tested in the long term and results are lower if compared with SNM.
Authors: Christopher L Langdale; James A Hokanson; Philip H Milliken; Arun Sridhar; Warren M Grill Journal: Am J Physiol Renal Physiol Date: 2020-04-20
Authors: Yihua Zhong; Jicheng Wang; Jonathan Beckel; William C de Groat; Changfeng Tai Journal: IEEE Trans Biomed Eng Date: 2021-09-20 Impact factor: 4.756
Authors: Jacek K Szymański; Aneta Słabuszewska-Jóźwiak; Kornelia Zaręba; Grzegorz Jakiel Journal: Wideochir Inne Tech Maloinwazyjne Date: 2019-05-23 Impact factor: 1.195